India’s National Pharmaceutical Pricing Authority caps price of 52 more drugs

15 December 2014

The National Pharmaceutical Pricing Authority (NPPA) of India has issued a notice capping prices of 52 essential drugs.

Under the Drugs Price Control Order, the government has capped the prices of drugs to treat cancer and skin disorders, as well as antibiotics and painkillers. The newly-named drugs join a list of nearly 400 medicines which are under price control in India.

The drugs include those from Indian drugmakers such as Wockhardt (BSE: WOCK), as well as foreign companies such as UK pharma major GlaxoSmithKline (LSE: GSK) and US drugmaker Baxter International (NYSE: BAX).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK